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Abstract
Pharmacogenetics provides great opportunity for improving both the chance of therapeutic benefit
and the ability to avoid adverse drug events. To date, the majority of pharmacogenetic studies have
been performed using germline DNA. DNA collection in most clinical trials provides a wealth of
samples from which pharmacogenetic studies can be launched. However, there is concern that the
data from germline DNA pharmacogenetics might be of limited value for diseases, such as cancer,
where germline variants may not adequately represent the genetic data obtained from the somatic
DNA. In this perspective, we evaluate the literature that compares pharmacogenetic variants between
germline DNA and matched somatic DNA. The analysis of these studies indicates that there is almost
complete concordance between germline and somatic DNA in variants of pharmacogenetic genes.
Although somatic variants are clinically significant and independently provide genetic information
that cannot be gained from the germline, the use of germline DNA for pharmacogenetic studies is




Pharmacogenetics provides great opportunity for improving both the chance of therapeutic
benefit and the ability to avoid adverse drug events. To date, the majority of pharmacogenetic
studies have been performed using germline DNA extracted from a patient’s blood or buccal
specimen. This is largely due to the ease of collection of these specimens and the existing DNA
extraction infrastructure preference for these matrices. At this point, many clinical trials,
regardless of their disease focus or end point, request germline DNA collection (typically from
blood or buccal specimens) upon study initiation. This provides a wealth of samples from which
pharmacogenetic studies can be launched. However, there is concern that the data from
germline DNA pharmacogenetics might be of limited value for diseases, such as cancer, where
germline, or inherited, DNA variants may not adequately represent the genetic data obtained
from the somatic, or acquired, DNA from the tumor tissue. The concern goes both ways, as
often the only available patient tissue is formalin-fixed paraffin-embedded (FFPE) tumor
tissue, raising the issue of suitability for toxicity predictor in germline tissues. Thankfully,
there is data to address this important element of translational genomics. In this perspective,
we summarize the literature that compares pharmacogenetic variants between germline DNA
and matched somatic DNA. In addition, we address the predictive value of somatic DNA
variants. Our analysis of the comparison studies indicates that there is almost complete
concordance between variants in the pharmacogenetic genes examined in germline and somatic
DNA (Figure 1). We conclude that while both germ-line and somatic DNA are of great
†Author for correspondence: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, Campus Box 7360,
Kerr Hall, Chapel Hill, NC 27599-7360, USA, Tel.: +1 919 966 0512; Fax: +1 919 962 0644; E-mail: hmcleod@unc.edu.
For reprint orders, please contact: reprints@futuremedicine.com
NIH Public Access
Author Manuscript
Pharmacogenomics. Author manuscript; available in PMC 2010 January 1.
Published in final edited form as:













importance in cancer, germline DNA provides a reliable and easily available resource and
should continue to be the primary genetic source for pharmacogenetic studies.
The studies reviewed below assess the concordance between variants from germline and tumor
DNA as well as germline DNA from blood compared with germline DNA from FFPE normal
adjacent tissue in not only genes with previously established roles in pharmacogenetics [1–
3], but also genes shown to be involved in other physiological functions, including angiogenesis
and breast cancer pathogenesis [4,5]. It has been shown that SNPs in an individual’s germline
play a role in the development of cancers. Therefore, establishing the concordance between
germline and somatic DNA variants may have value for cancer biology, variability in drug
response, and possibly in development of cancers and metastasis [6]. Table 1 summarizes the
findings of the discussed manuscripts, describes the tissues being compared, and most
importantly the concordance between the germline and tumor genotypes. The studies are
grouped into two categories based on the type of preparation used for the tissues genotyped,
including fresh/frozen tissue or paraffin-embedded tissue.
Genotype comparison using fresh/frozen tumor & germline tissue samples
Prospective correlative science studies most often obtain fresh/frozen tissue for analysis. The
sources from which DNA is extracted are typically blood samples for germline DNA and
surgical resection or bone marrow biopsy samples for somatic/tumor DNA. Weiss et al.
examined common pharmacogenetic gene polymorphisms in acute myeloid leukemia [3].
Because leukemia has frequent cytogenetic abnormalities, discordance between host and tumor
DNA genotypes may be relevant for pharmacogenetic studies. The authors genotyped 21 SNPs
and two gene deletions in 17 genes encoding proteins involved in drug metabolism, protection
from oxidative stress, drug transport and DNA repair. The authors sought to examine the
concordance between genotypes from paired pretreatment bone marrow samples (somatic/
tumor) and nondiseased tissue from buccal cell samples (germline) from 80 adult acute myeloid
leukemia patients. The results of these genetic comparisons indicated that 90% of the samples
had complete concordance for all SNPs examined, while that value increased to 97% of
individuals having one or less discrepant SNP (<4%, see Table 1) between the buccal and bone
marrow DNA [3].
Marsh et al. performed a similar comparison in colorectal cancer [1]. The colorectal tumor and
normal colon (germline) tissue were immediately frozen following surgical resection. This was
followed by extraction of the genetic material and genotyping for 28 SNPs and one tandem
repeat. The results of this genotype comparison showed that 41 out of 44 (93%) patient samples
had one or less discordant genotypes between the germline and tumor DNA. Overall, there
were 13 discordant genotypes of the 1139 comparisons (1.1%). In addition, because
microsatellite instability is a hallmark of colorectal cancer, the authors sought to examine
whether microsatellite-instability status corresponded with discordance. They found that
although eight cases (20%) had microsatellite instability, this was not statistically significantly
associated with genotype discordance (p = 0.67) [1]. Together, the studies of Weiss et al. and
Marsh and colleagues establish that germline DNA genotype is highly conserved in DNA from
fresh/frozen tumor tissue.
Genotype comparison using paraffin-embedded tumor samples & germline
samples
For many large clinical trials the only available tissue for any correlative studies is FFPE tissue
from either biopsy or resection. Schneider et al. addressed the issue of germline versus somatic
DNA genotype by examining three polymorphisms, two in eNOS and one in VEGF. Because
of the therapeutic and prognostic role of angiogenesis in breast cancer, 53 breast cancer tissue
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specimens from 21 patients were collected for this study. These included: 17 primary breast
cancer, 17 involved lymph node and 19 uninvolved lymph node specimens. DNA samples
were extracted from paraffin-embedded tissue. The authors analyzed well-established
polymorphisms with high frequencies and potential functional consequence, including a the
−786T>C polymorphism in the promoter and 894T>G (Glu298Asp) SNP in exon 7 of
eNOS, and the 936C>T SNP in VEGF. The 21 different individuals with primary tumor and
paired lymph node had 100% concordance between primary tumors and either involved or
uninvolved lymph nodes. In addition to this finding, because the authors used concordance, it
can be seen regardless of the part of tumor region that the DNA was extracted from in the
paraffin block. This is an additional level of confidence in the concordance between germline
and somatic DNA [4].
Rae et al. performed a similar study to examine the feasibility and accuracy of pharmacogenetic
genotyping in a number of sample preparation techniques. They compared ten DNA samples
isolated from whole blood with DNA isolated from the matched paraffin-embedded tumor
sample. When genotyping a CYP2C8 SNP, two CYP2D6 SNPs and an ABCB1 SNP, they found
100% concordance between germline and somatic genotypes [2]. Therefore, the authors
concluded, using a multi-tiered approach, that by using a high-yield DNA extraction method,
one can reliably obtain concordant genotypes between these paraffin-embedded cells and their
matched blood DNA sample.
Xie et al. also performed genotyping on paraffin-embedded normal tissue adjacent to breast
cancer compared with germline blood DNA. Often, the adjacent tissue will exhibit loss of
heterozygosity (LOH) in the stromal tissue surrounding the tumor [7]. It has been proposed
that this LOH could alter the genotyping results if the ‘normal’ tissue was extracted in the field
surrounding the tumor. SNPs in five genes that can be altered in breast cancer were evaluated;
MTHFR, hOGG1, DBH, DRD2 and NQO1. For each of the five genes, between 95–99% of
the 106 blood/tissue pairs produced genotyping results. One SNP in each gene was genotyped.
In all five genes, 100% of the sample pairs that were genotyped produced concordant genotypes
[5]. Although these results may reflect that the cells being genotyped were primarily stromal
cells that do not harbor LOH, the numbers are convincing that the paraffin-embedded adjacent
tissue can be used as ‘normal’ for genetic analysis. For this particular study, further genotyping
on pharmacogenetic specific genes would need to be performed to assess whether this
conclusion could be extrapolated from the breast cancer genes to pharmacogenetics as well.
The above described studies cover key issues for the use of a tumor sample, including DNA
extraction methods, paraffin-embedding and tissue staining. They compare the genotypes as
compared with their germline (either blood or buccal originated) counterparts. The studies
encompass colorectal cancer, breast cancer, acute myeloid leukemia and general tumors across
pharmacogenetic and other cancer genes. The results consistently show that concordance
between germline and tumor DNA genotypes is virtually 100% (Figure 1). Additionally, there
is almost 100% concordance between fresh tumor cells and paraffin-embedded cells. Further,
Xie et al. concluded that paraffin-embedded normal adjacent tissue to a breast cancer tumor is
100% concordant with germline DNA from blood [5]. A number of preliminary conclusions
can be drawn. Paraffin-embedded adjacent normal tissue can be used for normal tissue
genotyping. This fixation method has only been applied to pharmacogenetic studies since 2003
and represents a source of genetic material that is accurate and useful [2,8]. In the studies
reviewed above, paraffin-embedded tissue or cells can be genotyped with the same confidence
as fresh tissue or cells, at least using the methods applied in the reviewed studies. Also, germline
DNA from either blood or buccal cells can be genotyped for pharmacogenetic genes and the
concordance with tumor DNA is virtually 100%.
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There is predictive value in both germline DNA variants as well as somatic DNA variants.
Somatic variants in many cancer-related genes are clinically significant and the effects of these
mutations have implications on therapy. Many therapeutic agents have been designed to target
the somatic change through the disruption of essential signaling pathways. Because of their
role in tumorigenesis, kinases are the initial targets of many clinically-approved oncology drugs
[9]. Somatic mutations in the kinase domain of EGFR are seen in the tumor tissue of non-small-
cell lung cancer patients and are associated with increased response to gefitinib [10,11]. These
mutations are present in the tumor prior to therapy. Imatinib targets the breakpoint of BCR-
ABL translocation in the treatment of chronic myeloid leukemia [12]. Interestingly, the patient
will typically become resistant to imatinib, most commonly due to BCR-ABL acquiring a
somatic point mutation [13]. These somatic variants in chronic myeloid leukemia patients
resistant to imatinib provide powerful information that will affect the course of the treatment.
Somatic mutations in KIT have been reported in mast cell diseases, gastrointestinal stromal
tumors, and familial testicular germ-cell tumors [14]. Because imatinib also has specificity for
KIT, clinical trials have shown an increase in response [15].
Loss-of-heterozygosity is commonly seen in cancers. LOH occurs when an individual has
inherited a gene that has one allele inactivated and subsequently the second allele becomes
inactivated by a mutation in the tumor, resulting in loss-of-function. Tumor-suppressor genes
often become inactivated in oncology, resulting in tumorigenesis. In the presence of LOH,
germline DNA would have a higher frequency of heterozygotes than the corresponding somatic
DNA. To our knowledge, this has not presented any complications in genotyping with the
exception of one study. In a study examining the tandem repeat sequence in the
pharmacogenetic gene TYMS, Marsh et al. noted that in one out of 45 colorectal cancer patients
the genotype was not identical between paired samples of colorectal tumor and normal tissue
[16].
In conclusion, the use of germline DNA for pharmacogenetic studies is achievable and
valuable. There is almost complete concordance between variants in pharmacogenetic genes
between germline and somatic DNA as described above. Germline DNA is easily obtained and
more readily available than somatic DNA. Somatic variants also provide significant predictive
value. In some cases, somatic variants can be specifically targeted resulting in increased
response. However, in pharmacogenetic studies, the availability and accuracy of germline
DNA offers great opportunities for the implementation of individualized therapy in a timely
fashion.
Future perspective
Pharmacogenetics is at an early point in its evolution – currently there are only a few genotypes
that have shown a significant clinical impact on the individual patient. As the cost of whole-
genome sequencing decreases over the next few years, targeted therapy for cancer will become
more achievable. However, the amount of genetic information available for a given patient
will far exceed current ability to translate it into better care.
Many current clinical trials and likely all future clinical trials will require the archiving of many
sources of the patient’s molecular information. This will include germline DNA (from blood
or buccal cells) or somatic DNA from the tissue specimens. To date, there have been only five
publications directly addressing the issue of concordance between germline and somatic DNA
in pharmacogenetics [1–5]. Because of the current limitation of available tissue in practice-
changing clinical trials, the near future will bring an even greater need for understanding how
DNA from fresh/frozen somatic/tumor DNA, germline DNA from blood/buccal cells, FFPE
somatic/tumor or FFPE germline DNA from adjacent normal tissue can be used to better select
populations of patients with the greatest risk–benefit relationship. These large, comprehensive
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studies will provide the concrete evidence that many researchers will require before relying on
the use of only germline DNA for cancer studies. It is possible that the increased availability
of both tumor and germline DNA from a patient will eliminate the need to rely exclusively on
one or the other. However, in order to fully understand the disease and treat the patient in the
most comprehensive manner, both the germline and somatic variants will require precise
examination. Each has unique predictive value for different reasons. This fact will be consistent
throughout time.
Executive summary
• Concordance between matched germline (blood/buccal) and somatic (tumor-fresh/
frozen) DNA is 93–100% for pharmacogenetic genotypes.
• Concordance between matched formalin-fixed paraffin embedded (FFPE)
germline versus FFPE somatic DNA and between matched FFPE adjacent tissue
versus blood is 100% for pharmacogenetic genotypes.
• FFPE tissue provides an accurate source of DNA for pharmacogenetic studies.
• Germline DNA is sufficient for genetic analysis of pharmacogenetic genes.
• Somatic DNA provides unique information that can have significant implications
when the therapy has a molecular target in the tumor.
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Figure 1. Concordance for 74 SNPs across five studies
The legend indicates number of reference. The X-axis shows each individual SNP for each
study, while the Y-axis describes the concordance between the two tissues compared in each
specific study. The concordance value can be between 0 (no concordance) and 1 (complete
concordance), but clearly cluster between 0.9 and 1.0 in the studies examined.
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